PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract
PharmAla Biotech Holdings Inc. (OTC:MDXXF), a Toronto-based biotechnology company, has secured a contract to supply MDMA for a clinical trial conducted by Johns Hopkins Medicine. This marks a significant milestone for the company as it expands its role in providing MDMA and its novel derivatives for scientific and medical research. PharmAla specializes in the research, development and manufacturing of LaNeo MDMA and related MDXX class molecules, which have garnered attention for their potential in therapeutic applications.
Supplying Johns Hopkins With GMP Certified MDMA
The CEO of PharmAla Biotech, Nicholas Kadysh, expressed the company’s commitment to supporting groundbreaking research globally. “We’re looking …